Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

PROTAGONIST THERAPEUTICS, INC.

(PTGX)
  Report
Delayed Nasdaq  -  04:00:00 2023-02-07 pm EST
15.83 USD   +5.82%
01/11Transcript : Protagonist Therapeutics, Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-11-2023 07:30 AM
CI
01/06Protagonist Therapeutics, Inc : Change in Directors or Principal Officers (form 8-K)
AQ
01/06Protagonist Therapeutics, Inc. Announces David Liu, Chief R&D Strategy Officer, Transitioned to Part-Time R&D Strategy Advisor
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Valuation
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Capitalization1 1928671 632779779-
Enterprise Value (EV)1 68,65611 305730570418
P/E ratio -2,37x-10,5x-12,6x-6,18x-5,44x-7,39x
Yield ------
Capitalization / Revenue 830x30,3x59,7x24,7x89,0x14,1x
EV / Revenue 297x19,6x47,7x23,2x65,1x7,57x
EV / EBITDA --8,81x-10,4x-5,70x-4,04x-2,68x
Enterprise Value (EV) / FCF -1,62x-7,70x-12,0x-7,45x-3,42x-2,18x
FCF Yield -61,8%-13,0%-8,35%-13,4%-29,2%-45,8%
Price to Book ------
Nbr of stocks (in thousands) 27 20643 01947 72849 19849 198-
Reference price (USD) 7,0520,234,215,815,815,8
Announcement Date 03/10/202003/10/202102/28/2022---
1 USD in Million
Previous periodNext period
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales1 0,2328,627,431,58,7555,2
EBITDA1 --63,7-125-128-141-156
Operating profit (EBIT)1 -80,5-64,5-126-128-154-128
Operating Margin -34 858%-225%-460%-407%-1 758%-232%
Pre-Tax Profit (EBT)1 -77,9-64,8-126-127-137-76,0
Net income1 -77,2-66,2-126-127-153-127
Net margin -33 414%-231%-459%-402%-1 747%-230%
EPS2 -2,98-1,92-2,71-2,56-2,91-2,14
Free Cash Flow1 -42,4-73,0-109-98,0-167-192
FCF margin -18 355%-255%-398%-311%-1 903%-347%
FCF Conversion -114%87,2%76,6%118%123%
Dividend per Share ------
Announcement Date 03/10/202003/10/202102/28/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2
Net sales1 25,70,86-5,003,331,67
EBITDA1 -20,9-41,2-32,0-33,0--
Operating profit (EBIT)1 -21,1-41,4-32,3-32,2-43,1-39,0
Operating Margin -82,1%-4 825%--645%-1 292%-2 341%
Pre-Tax Profit (EBT)1 -20,9-41,0-31,2-33,6-43,1-39,0
Net income1 -20,9-41,0-31,2-32,0-38,0-36,2
Net margin -81,4%-4 777%--640%-1 140%-2 169%
EPS2 -0,43-0,84-0,64-0,64-0,69-0,71
Dividend per Share ------
Announcement Date 05/04/202208/04/202211/08/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt1 ------
Net Cash position1 12330632749,0209361
Leverage (Debt / EBITDA) -4,80x2,61x0,38x1,48x2,31x
Free Cash Flow1 -42,4-73,0-109-98,0-167-192
ROE (Net Profit / Equities) --36,8%-43,3%-50,3%-48,6%-34,7%
Shareholders' equity1 -180290252314366
ROA (Net Profit / Asset) --27,6%-37,4%-39,9%-37,8%-29,3%
Assets1 -240336317404433
Book Value Per Share ------
Cash Flow per Share ------
Capex1 0,970,471,10---
Capex / Sales 419%1,65%4,02%---
Announcement Date 03/10/202003/10/202102/28/2022---
1 USD in Million
Previous periodNext period
Estimates
Key data
Capitalization (USD) 778 810 846
Net sales (USD) 27 357 000
Number of employees 122
Sales / Employee (USD) 224 238
Free-Float 98,5%
Free-Float capitalization (USD) 767 476 471
Avg. Exchange 20 sessions (USD) 17 131 152
Average Daily Capital Traded 2,20%
EPS & Dividend